ATP5MC3

Across TCGA pan-cancer cohorts, ATP5MC3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ATP5MC3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATP5MC3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP5MC3 expression acts as an unfavorable survival marker.

HNSC, PAAD, and BLCA are the cancer types where ATP5MC3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.224	0.752	<.001	33	view →
PAAD	OS	Median	All	0.117	0.613	<.001	21	view →
BLCA	DFS	Median	All	0.163	0.625	.018	15	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ATP5MC3–HNSC (OS)

Open the HNSC breakdown →